AM-Pharma B.V.

Cost-cutting has become the norm for biopharmaceutical companies in 2023 as drug developers struggle to raise capital for ongoing research and development programs, never mind bringing in new funding

With sentiment turning against the biotech sector in the public markets, leading European life science venture capital firm Forbion has put together a new fund that could be worth €600m to tap into so

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sanofi Bangladesh Acquisition Adds To B

Venture capital investment in biopharmaceutical companies has been remarkable throughout 2020, both in terms of individual company fundraisings and new VC funds, including two funds totaling $755m tha